Following strong nine-month sales of the influenza treatment, Tamiflu (oseltamivir) and the cancer drug, Avastin (bevacizumab), the Roche Group has raised its guidance for sales growth in 2009 and confirmed its estimates for profit growth. ---Subscribe to MedNous to access this article--- Company News
